Basal cell carcinoma treatment cost in Seoul

Every treatment this condition maps to, cheapest first — diagnostics before treatments. Each links to its full price comparison. One pathway per patient; we never sum options into a fake total.

Each treatment links to its full price page — clinic prices, other cities, recovery and risks.

Your first spend is the work-up, not the treatment — the typical items, priced from this registry where we hold them.

Consultation fees from our specialist registry; procedure prices from this condition's mapped diagnostics. Unverified prices are labeled on their own pages.

The actual decision at this stage: the recurring cost of living with the condition vs the one-time treatment pathway. Unit prices only — we never extrapolate an annual total.

The go/no-go math everyone does on a napkin, done transparently: price here plus trip costs from United States (change in the header) — flying beats staying when your quote at home is above the line.

Trip = flights, hotel, transport and medication from the same model as the all-in estimates — labeled estimates, not quotes. If your quote at home is below the line, staying home wins on pure price; quality, waits and urgency are separate calls — see the MCI index above.

The same care market across the registry — cheapest entry first. Cheapest ≠ best: the MCI column grades each market as its data lands.

• Public-system wait at home (UK)NHS England referral-to-treatment statistics, Apr 2026 · Canada (CIHI) next 11.9-week median
• Recruiting basal cell carcinoma trials in South KoreaClinicalTrials.gov — recruiting "cancer" studies with a South Korea site · queried 2026-07-09 811 studies
• JCI-accredited organizations in South KoreaJCI public directory, country-wide (all specialties) Not yet sourced

Cheapest entry price per city with the size of its priced treatment menu and specialist density — countable signals only, "—" is never guessed.

The best hospitals first — Newsweek World's Best national top 10 lead, then our connected-chain grade. Re-rank by rating or reviews.

Destination-safety factor for South Korea: ×1.00 — Level 1 — Exercise Normal Precautions (the lowest advisory tier) (US State Dept Travel Advisory, 2025-08). Applies equally to every hospital here; it separates this market from higher-risk destinations.

Epidemiology slots — filled only from named registry sources, never estimated.

Having your existing diagnosis re-read here is the cheapest way to test a hospital's quality before booking anything. Prices land per hospital with sources — never estimated.

• Remote records review — written second opinion your existing scans, pathology and reports, reviewed without flying Not yet priced
• Video consultation with a specialist live case discussion after the review Not yet priced
• In-person specialist consultation reference price if you're already here · Oncologist from $37

A second opinion changes the plan often enough that specialists expect to be asked for one — it's a normal request, not an insult. Remote-review prices are being collected per hospital.

How the treatment decision is typically made for this condition — your specialist confirms the path for your case.

1. 1

   See the right specialist

   Care for basal cell carcinoma starts with a specialist, who confirms the diagnosis and plans the next steps.

2. 2

   Diagnosis & tests

   The diagnosis is confirmed with Tissue and Specimen Analysis (Biopsy), which also show how far it has progressed (staging).

3. 3

   Treatment options

   Options include Tumor Resection, Surgical Oncology, Radiation Therapy or Photodynamic Therapy (PDT) — weighed on outcome, downtime, risk and total cost. See the priced menu and decision factors below.

4. 4

   Treatment

   The chosen treatment plan is carried out — every option below links to its own price page with a recovery timeline.

5. 5

   Follow-up & monitoring

   Scheduled scans and check-ups confirm the result and catch any recurrence early; remote follow-up is common for international patients.

Framework pathway modeled by field — per-condition clinical pathways replace it as they're sourced.

Specialist types by pathway phase — never named individuals — with real consultation fees where we hold them. Each links to its own price page.

• Diagnosis Radiologist reads your imaging consult from $37
• Diagnosis Pathologist confirms the diagnosis from the biopsy consult from $37
• Decision & systemic treatment Oncologist stages the disease and owns the treatment plan consult from $37
• Local treatment Radiation therapist plans and delivers radiotherapy Fee not yet priced

Fees are city-level consultation ranges from our specialist registry (imported, re-verified over time). Doctors are hospital attributes — you choose the provider on its hospital page, never a named individual here.

What actually decides between the treatments above — and the checklist an expert would put to the specialist.

A planning frame — suitability is always the specialist's call.

What matters if it goes wrong, and what it takes to get there — country-level, verifiable guidance in one place.

Visa

Most Western nationalities (US, UK, EU/Schengen, Australia, Canada, New Zealand, Japan) enter visa-free for short medical or tourist visits. The K-ETA (electronic travel authorization) requirement is temporarily WAIVED for 67 countries and territories through 31 December 2026 — eligible travellers enter without applying for a K-ETA; the requirement is expected to resume 1 January 2027. Confirm your nationality's current rule before travelling.

Medical / long-stay visa

For treatment, foreign patients typically use the C-3-3 medical tourism visa (short-term, stays up to 90 days, generally not extendable beyond 90 days except in special circumstances). For treatment or recovery longer than 90 days, patients change to or apply for the G-1-10 long-term medical treatment visa, which can be extended inside Korea; it requires hospital documentation (medical opinion, treatment schedule, payment records). Applications must be tied to a medical institution registered with KTO/KHIDI.

Arrival

From 1 January 2026, all foreign arrivals must file the mandatory digital e-Arrival Card online (within 3 days before arrival) — it replaces the paper disembarkation card and is a declaration, not a visa. Travellers who hold an approved K-ETA are exempt from the arrival card, but nationals of K-ETA-waived countries (US, UK, EU, Japan, etc.) must still complete the e-Arrival Card.

Currency

South Korean Won (KRW, ₩)

Languages

Korean; English widely spoken in international-patient centers at major hospitals, with interpreter services in multiple languages

Traveller safety

Very safe for visitors

Legal recourse

Established malpractice recourse

Insurance

Medical-travel & complication cover widely available

International patients

Hospitals accustomed to international patients

General guidance from public sources — confirm current rules for your nationality. Verified against: Korea Immigration — K-ETA temporary exemption extended to 31 Dec 2026 (MOFA/KPMG GMS alert) · Korea e-Arrival Card mandatory from 1 Jan 2026 · Medical Korea — medical visa (C-3-3 / G-1-10), KHIDI · MOHW — Korea attracts 1.17 million foreign patients in 2024.

One comparable grade for this city's care market for the diagnosis — treatment coverage, price, evidence, choice and provider trust on the same public formula. Unsourced metrics are excluded, never guessed.

Who treats basal cell carcinoma, and nearby diagnoses in the same field.

Dots carry the lens colors — teal opens a specialist page, red another condition, both priced for Seoul.

Short answers built from the numbers on this page — costs, pathway, providers and verification.

How much of this page is verified data — every section carries a chip telling you where its numbers come from.